In a report released today, Gil Blum from Needham maintained a Buy rating on Autolus Therapeutics (AUTL – Research Report), with a price target of $13.00. The company’s shares closed last Monday at $2.28, close to its 52-week low of $2.20.
According to TipRanks.com, Blum is ranked 0 out of 5 stars with an average return of -36.2% and a 18.6% success rate. Blum covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Rocket Pharmaceuticals, and Aeglea Biotherapeutics.
Currently, the analyst consensus on Autolus Therapeutics is a Strong Buy with an average price target of $14.00, a 444.7% upside from current levels. In a report released yesterday, Mizuho Securities also maintained a Buy rating on the stock with a $18.00 price target.
Based on Autolus Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $37.06 million. In comparison, last year the company had a GAAP net loss of $33.27 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm’s portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom.
Read More on AUTL:
- How Will Uber & Delta Airlines Perform Amid Rising Oil Prices?
- Oracle (ORCL) Receives a Buy from Monness
- RBC Capital Thinks Bank of America’s Stock is Going to Recover
- Credit Suisse Thinks Ardagh Metal Packaging’s Stock is Going to Recover
- Needham Thinks Selecta Biosciences’ Stock is Going to Recover